Biovica International (BIOVIC) Q1 26/27 earnings summary

Executive summary

• Achieved 56% year-over-year net sales growth in Q1, primarily driven by strong Pharma Services momentum.

• Implemented organizational restructuring and cost-saving measures, including leadership changes and a refocused US commercial strategy.

• Strengthened leadership with a new CEO and CFO, and proposed a renewed Board with commercial and life sciences expertise.

• Positioned for the next phase of growth with a fully guaranteed SEK 29.2 million rights issue.

Financial highlights

• Net sales reached KSEK 4,043, up from KSEK 2,596, a 56% increase year-over-year (57% in local currency).

• Operating loss (EBIT) was KSEK -20,334, compared to KSEK -19,334, including KSEK 2,200 in restructuring costs.

• Cash flow from operating activities improved to KSEK -16,100 from KSEK -17,196.

• Cash and cash equivalents at quarter-end were KSEK 51,588, up from KSEK 16,305.

• Earnings per share after dilution was SEK -0.07, compared to SEK -0.18 year-over-year.

Outlook and guidance

• Updated strategic and financial plan to be communicated in the coming months.

• Confident in having sufficient financial resources for at least twelve months, subject to rights issue completion.

• Focus remains on sustainable, profitable growth through scientific innovation and commercial execution.